EUCTR2005-005665-11-IT进行中（未招募）不适用
EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL WITH AN OPTIONAL LONG-TERM OPEN-LABEL EXTENSION PHASE - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- RECORDATI
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Male subjects aged 50 years or older; 2. Presence at Visits 2 start of placebo run-in and 3 baseline , of an IPSS-1 score of 13; 3. Presence of less than 25 decrease of the IPSS-1 score between Visit 2 start of placebo run-in and Visit 3 baseline ; 4. Presence at Visits 2 start of placebo run-in and 3 baseline , of bladder outlet obstruction, as defined by a Qmax peak urine flow rate between 4 and 15 mL/sec, with a minimum voided volume of 125 mL; 5. Presence of a satisfactory compliance to study medication 80-120 at Visit 3 baseline ; 6. Able to comply with protocol procedures; 7. Able to give written informed consent before beginning any investigational procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Post void bladder residual vol. of greater than 250mL; 2.Intravesical obstruct. from any cause other than BPH ; 3.Bladder calculi; 4.History of, or current, neurogenic bladder and other conditions that may affect bladder function; 5.History of any type of procedure in the past that is considered intervention for BPH or bladder neck obstruction; 6.An active urin. tract inf., or a history of recurrent urin. tract inf.; 7.Current prostatitis or a diagnosis of chronic prostatitis; 8.History of urinary retention, from a cause other than BPH, within the past 3 months; 9.History of prior prostate cancer, or prostate cancer as suspected by TRUS, DRE or clinical acumen. Subjects with a PSA greater than 10.0 ng/ml will be excluded. Subjects with a PSA between 4.0 and 10.0 should have prostate cancer ruled out to the satisfaction of the clinical Investigator with appropriate documentation of the physician s assessment; 10.History of prior invasive bladder cancer; 11.Prior radiation to the pelvis regardless of the reason or dosage of radiation; 12.Bladder catheterization or bladder or prostate instrumentation within the past 30 days; 13.History of, or current significant postural hypotension, and/or have experienced significant postural hypotension upon initiating therapy with an alfa-blocker.; 14.Clinical significant cardiovascular and cerebrovascular disease in the last 6mo; 15.Poorly controlled diabetes HbA1c 8 ; 16.Renal insuff. serum creatinine 2.0 mg/dL ; 17.Liver insuff. any LFT 2xULN ;18.Hematuria which has not been appropriately evaluated to determine safe subject participation;19.Rec. episodes of dizziness, vertigo, or loss of consciousness; 20.Pelvic surgery for malignancy or bowel resection; 21.History or current evidence of drug or alcohol abuse within the last 12 months; 22.History of allergy to alfa-blockers, or to any of the inactive agents used in this formulation; 23.Uncontrolled hypo- or hyperthyroidism; 24.Participation in a study involving the admin. of an inv. compound within the past 30days, or within 5times the half life of the prior inv. drug, whichever is longer; 25.Any subject, in the investigator s opinion, not considered suitable for enrolment; 26.History of inadequate clin. resp. to the use of alfa-blockers spec. for the release of BPH symptoms; 27.Receiving med. after V1,which preclude safe part. in the study or that may produce a confounding effect on the var.under study.
研究者
相似试验
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1 Level: LLT Classification code 10004446EUCTR2005-005665-11-GBRecordati S.p.A1,400
进行中（未招募）
不适用
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseEUCTR2005-005665-11-FIRecordati S.p.A1,400
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1Level: LLTClassification code 10004446EUCTR2005-005665-11-ESRecordati S.p.A1,400
招募中
不适用
sildosin 2 mg versus sildosin 4 mg in premature ejaculation: a prospective studyurologyJPRN-UMIN000038663AlAzhar university100
进行中（未招募）
不适用
EFFECTIVENESS AND SAFETY OF SILODOSIN IN THE TREATMENT OF LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A EUROPEAN PHASE IV CLINICAL STUDY - SiREEUCTR2011-000045-20-ITRECORDATI1,000